Fabricating the Multibranch Carboxyl-Modified Cellulose for Hemorrhage Control
December 2023
in “
Materials Today Bio
”
Studysummary This study found that modified microcrystalline cellulose with citric and ascorbic acid demonstrated enhanced hemostatic properties and biocompatibility in vitro and in animal hemorrhage models.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study investigated the potential of multibranch carboxyl-modified cellulose (MCAA) as a hemostatic material for hemorrhage control. By modifying microcrystalline cellulose with citric and ascorbic acids, the carboxyl content was increased to 9.52%, enhancing its ability to absorb plasma and stimulate platelets. The MCAA demonstrated higher thermal stability and excellent biocompatibility, with a hemolysis ratio of less than 1% and cell viability exceeding 100% after 72 hours. In vitro and in vivo tests showed that MCAA significantly improved hemostatic properties, accelerating coagulation through platelet aggregation and clotting cascade activation, while causing minimal skin irritation. These findings suggest that MCAA is a safe and effective hemostatic agent.
